Leerink Partnrs Comments on AxoGen FY2029 Earnings

AxoGen, Inc. (NASDAQ:AXGN - Free Report) - Equities researchers at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for AxoGen in a research report issued to clients and investors on Tuesday, February 25th. Leerink Partnrs analyst M. Kratky anticipates that the medical equipment provider will post earnings of $0.38 per share for the year. The consensus estimate for AxoGen's current full-year earnings is ($0.29) per share.

Separately, Canaccord Genuity Group boosted their price target on AxoGen from $22.00 to $26.00 and gave the company a "buy" rating in a research report on Wednesday, February 26th.

AxoGen Trading Down 0.6 %

AXGN stock traded down $0.12 during trading on Friday, reaching $19.89. 149,682 shares of the stock traded hands, compared to its average volume of 532,278. The business's 50 day moving average price is $17.75 and its 200-day moving average price is $15.11. AxoGen has a 52-week low of $5.55 and a 52-week high of $21.00. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. The firm has a market capitalization of $875.32 million, a PE ratio of -62.32 and a beta of 1.00.

Institutional Investors Weigh In On AxoGen

A number of institutional investors have recently added to or reduced their stakes in the company. Divisadero Street Capital Management LP grew its position in AxoGen by 2.7% during the fourth quarter. Divisadero Street Capital Management LP now owns 26,972 shares of the medical equipment provider's stock valued at $444,000 after acquiring an additional 700 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of AxoGen by 4.0% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,128 shares of the medical equipment provider's stock worth $398,000 after purchasing an additional 926 shares in the last quarter. Principal Financial Group Inc. lifted its stake in shares of AxoGen by 8.3% during the fourth quarter. Principal Financial Group Inc. now owns 16,000 shares of the medical equipment provider's stock worth $264,000 after purchasing an additional 1,228 shares in the last quarter. Sentry Investment Management LLC lifted its stake in shares of AxoGen by 9.3% during the third quarter. Sentry Investment Management LLC now owns 17,368 shares of the medical equipment provider's stock worth $243,000 after purchasing an additional 1,483 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of AxoGen by 2.7% during the fourth quarter. Rhumbline Advisers now owns 58,232 shares of the medical equipment provider's stock worth $960,000 after purchasing an additional 1,521 shares in the last quarter. Hedge funds and other institutional investors own 80.29% of the company's stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.